DNAJC13 and Parkinson disease: Consistent evidence of retromer dysfunction in the different PD models, e.g., mutant DNAJC13 expression, mitochondrial toxicity, and excessive aS induction, implies that the retromer may be a target for disease-modifying therapy in PD.